Abstract
Although they may sometimes appear similar, paraneoplastic autoimmunity has a unique pathogenesis, different from the classical autoimmune diseases not associated with cancer. When distinguished clinically, paraneoplastic autoimmunity is more severe and often presents with a broader range of clinical signs and symptoms. Management of these patients is difficult and is usually centered in part on treatment of the underlying malignancy. Self-antigens recognized in the setting of paraneoplastic autoimmunity can be diverse, and the number of determinants recognized within a single antigen can be numerous. This review uses prototypic examples of paraneoplastic immune-mediated diseases and their associated malignancies to describe the mechanisms by which immune dysregulation can occur in the setting of cancer. Specific diseases covered include paraneoplastic pemphigus, Sweet’s syndrome, pyoderma gangrenosum, thymoma-associated multiorgan autoimmunity, myasthenia gravis, autoimmune hemolytic anemia, immune thrombocytopenia, and the paraneoplastic neurological syndromes. The malignancies discussed include thymoma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia, among others. The mechanisms by which cancers induce autoimmunity are broken down into the following categories: disruption of central tolerance, peripheral immune dysregulation, and alteration of self-antigens. For each category, examples of paraneoplastic autoimmune diseases and their associated malignancies are discussed. Finally, mechanisms by which cancer treatment can lead to autoimmunity and examples of polymorphisms that are linked to both cancer and autoimmunity are discussed.
Similar content being viewed by others
References
Amagai M, Nishikawa T, Nousari HC, Anhalt GJ, Hashimoto T (1998) Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest 102:775–782
Futei Y, Amagai M, Hashimoto T, Nishikawa T (2003) Conformational epitope mapping and IgG subclass distribution of desmoglein 3 in paraneoplastic pemphigus. J Am Acad Dermatol 49:1023–1028
Lehmann PV, Forsthuber T, Miller A, Sercarz EE (1992) Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358:155–157
Bowen GM et al (2000) Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenic trigger of epitope spreading? Arch Dermatol 136:652–656
Wang L, Bu D, Yang Y, Chen X, Zhu X (2004) Castleman’s tumours and production of autoantibody in paraneoplastic pemphigus. Lancet 363:525–531
Anhalt GJ et al (1990) Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 323:1729–1735
Sehgal VN, Srivastava G (2009) Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. Int J Dermatol 48:162–169
Ehst BD, Minzer-Conzetti K, Swerdlin A, Devere TS (2010) Cutaneous manifestations of internal malignancy. Curr Probl Surg 47:384–445
Martinez De Pablo MI et al (2005) Paraneoplastic pemphigus associated with non-Hodgkin B-cell lymphoma and good response to prednisone. Acta Derm Venereol 85:233–235
Mimouni D et al (2002) Paraneoplastic pemphigus in children and adolescents. Br J Dermatol 147:725–732
Billet SE, Grando SA, Pittelkow MR (2006) Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity 39:617–630
Buck T, Gonzalez LM, Lambert WC, Schwartz RA (2008) Sweet’s syndrome with hematologic disorders: a review and reappraisal. Int J Dermatol 47:775–782
Zappasodi P, Forno C, Corso A, Lazzarino M (2006) Mucocutaneous paraneoplastic syndromes in hematologic malignancies. Int J Dermatol 45:14–22
Sands J, Tuscano JM (2010) Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev 9:A335–A341
Perry HO, Brunsting LA (1957) Pyoderma gangrenosum; a clinical study of nineteen cases. AMA Arch Derm 75:380–386
Bernstein CN, Blanchard JF, Rawsthorne P, Yu N (2001) The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 96:1116–1122
Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG (2001) Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 137:930–933
Veloso FT, Carvalho J, Magro F (1996) Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 23:29–34
Brunsting LA, Goeckerman WH, O’Leary PA (1930) Pyoderma (echthyma) gangrenosum—clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syph 22:655–680
Bennett ML et al (2000) Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 79:37–46
Duguid CM, O’Loughlin S, Otridge B, Powell FC (1993) Paraneoplastic pyoderma gangrenosum. Australas J Dermatol 34:17–22
Oka M et al (2000) Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest 80:595–604
Oka M (2007) Pyoderma gangrenosum and interleukin 8. Br J Dermatol 157:1279–1281
Tanaka N, Fujioka A, Tajima S, Ishibashi A, Hirose S (2000) Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1 beta and tumour necrosis factor-alpha stimulate its secretion in vitro. Br J Dermatol 143:728–732
Saito S et al (2006) CD30+ anaplastic large cell lymphoma complicated by pyoderma gangrenosum with increased levels of serum cytokines. Eur J Haematol 77:251–254
Kawakami T, Yamazaki M, Soma Y (2009) Reduction of interleukin-6, interleukin-8, and anti-phosphatidylserine-prothrombin complex antibody by granulocyte and monocyte adsorption apheresis in a patient with pyoderma gangrenosum and ulcerative colitis. Am J Gastroenterol 104:2363–2364
Bister V, Makitalo L, Jeskanen L, Saarialho-Kere U (2007) Expression of MMP-9, MMP-10 and TNF-alpha and lack of epithelial MMP-1 and MMP-26 characterize pyoderma gangrenosum. J Cutan Pathol 34:889–898
Brooklyn TN et al (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55:505–509
Mittal S, Milner BJ, Vickers MA (2005) Pyoderma gangrenosum as a cause of splenomegaly and association with a T-cell clone. Clin Lab Haematol 27:402–404
Brooklyn TN, Williams AM, Dunnill MG, Probert CS (2007) T-cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking. Br J Dermatol 157:960–966
Su WP, Schroeter AL, Perry HO, Powell FC (1986) Histopathologic and immunopathologic study of pyoderma gangrenosum. J Cutan Pathol 13:323–330
Gapin L et al (1998) Quantitative analysis of the T cell repertoire selected by a single peptide-major histocompatibility complex. J Exp Med 187:1871–1883
Maverakis E et al (2003) Autoreactive T cells can be protected from tolerance induction through competition by flanking determinants for access to class II MHC. Proc Natl Acad Sci USA 100:5342–5347
Sercarz EE, Maverakis E (2003) Mhc-guided processing: binding of large antigen fragments. Nat Rev Immunol 3:621–629
Maverakis E, Beech JT, Schneider S, Sercarz EE (2008) Presentation of a determinant by MHC class II can be prevented through competitive capture by a flanking determinant on a multideterminant peptide. J Autoimmun 31:59–65
Gammon G, Sercarz E (1989) How some T cells escape tolerance induction. Nature 342:183–185
Engels EA, Pfeiffer RM (2003) Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 105:546–551
Melms A et al (2006) Thymus and myasthenia gravis: antigen processing in the human thymus and the consequences for the generation of autoreactive T cells. Acta Neurol Scand Suppl 183:12–13
Wadhera A et al (2007) Thymoma-associated multiorgan autoimmunity: A graft-versus-host-like disease. J Am Acad Dermatol 57(4):683–689
Nagvekar N et al (1998) A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. J Clin Invest 101:2268–2277
Moschella SL (1967) Pyoderma gangrenosum. A patient successfully treated with intralesional injections of steroid. Arch Dermatol 95:121–123
Jennings JL (1983) Pyoderma gangrenosum: successful treatment with intralesional steroids. J Am Acad Dermatol 9:575–580
Mrowietz U, Christophers E (1991) Clearing of pyoderma gangrenosum by intralesional cyclosporin A. Br J Dermatol 125:499
Rosenow EC 3rd, Hurley BT (1984) Disorders of the thymus. A review. Arch Intern Med 144:763–770
Lara PN Jr (2000) Malignant thymoma: current status and future directions. Cancer Treat Rev 26:127–131
Good RA (1954) Agammaglobulinaemia: a provocative experiment of nature. Bull Univ Minn Hosp 26:1–19
Fujimoto W et al (2002) Paraneoplastic pemphigus associated with Castleman’s disease and asymptomatic bronchiolitis obliterans. Eur J Dermatol 12:355–359
Wang J et al (2005) Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneoplastic pemphigus. Br J Dermatol 153:558–564
Wang J et al (2005) Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol 141:1285–1293
Nikolskaia OV, Nousari CH, Anhalt GJ (2003) Paraneoplastic pemphigus in association with Castleman’s disease. Br J Dermatol 149:1143–1151
Kim WY, Kim H, Jeon YK, Kim CW (2010) Follicular dendritic cell sarcoma with immature T-cell proliferation. Hum Pathol 41:129–133
Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP (1992) CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607–609
Thompson ED, Enriquez HL, Fu YX, Engelhard VH (2010) Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med 207:1791–1804
Hamblin TJ (2006) Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 33:230–239
Dearden C (2008) Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program, pp 450–456
Tomic J et al (2006) Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J Immunol 176:3830–3839
Jablonska E et al (2005) TNF family molecules in the serum of patients with B-cell chronic lymphocytic leukemia (B-CLL). Leuk Lymphoma 46:1307–1312
Hall AM, Vickers MA, McLeod E, Barker RN (2005) Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 105:2007–2015
Gorgun G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG (2005) Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 115:1797–1805
Ramsay AG et al (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 118:2427–2437
Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y (2001) Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 60:433–441
Cines DB, Bussel JB, Liebman HA, Luning Prak ET (2009) The ITP syndrome: pathogenic and clinical diversity. Blood 113:6511–6521
Beyer M et al (2005) Reduced frequencies and suppressive function of CD4 + CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106:2018–2025
Dearden C et al (2008) The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 111:1820–1826
Citores MJ et al (2010) CD154 expression triggered by purine analogues in vitro: correlation with treatment response and autoimmune events in chronic lymphocytic leukemia. Exp Hematol 38:165–173
Gooptu C et al (2001) Paraneoplastic pemphigus: an association with fludarabine? Br J Dermatol 144:1255–1261
Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
Di Bernardo MC et al (2008) A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 40:1204–1210
Shaffer AL et al (2008) IRF4 addiction in multiple myeloma. Nature 454:226–231
Biswas PS et al (2010) Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest 120:3280–3295
Novak AJ et al (2009) Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res 69:4217–4224
Juszczynski P et al (2002) Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood 100:3037–3040
Chu VT et al (2009) Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 60:2083–2093
Zhang W et al (2010) B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci USA 107:18956–18960
Lang B, Vincent A (1996) Autoimmunity to ion-channels and other proteins in paraneoplastic disorders. Curr Opin Immunol 8:865–871
Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y (2001) The dual association between lymphoma and autoimmunity. Blood Cell Mol Diseases 27:750–756
Dalmau J et al (2007) Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61:25–36
Butler MH et al (2000) Autoimmunity to gephyrin in Stiff–Man syndrome. Neuron 26:307–312
Polans AS et al (1995) Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proc Natl Acad Sci USA 92:9176–9180
Buckanovich RJ, Yang YYL, Darnell RB (1996) The onconeural antigen Nova-1 is a neuron-specific RNA-Binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci 16:1114–1122
Lennon VA et al (1995) Calcium-channel antibodies in the Lambert–Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 332:1467–1474
Yu Z et al (2001) CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49:146–154
Acknowledgments
EM holds career awards from the Burroughs Wellcome Fund and the Howard Hughes Medical Institute.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maverakis, E., Goodarzi, H., Wehrli, L.N. et al. The Etiology of Paraneoplastic Autoimmunity. Clinic Rev Allerg Immunol 42, 135–144 (2012). https://doi.org/10.1007/s12016-010-8248-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-010-8248-5